SCHEMBL1863099

SCHEMBL1863099

Cc1ccc(S(=O)(=O)NN(CCCC2(O)CCCCC2)C(=O)OC(C)(C)C)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.37
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
POLB P06746 1/20 0.34
ALDH1A1 P00352 5/20 0.34
TSHR P16473 2/20 0.34
MAPT P10636 2/20 0.34
KDM4E B2RXH2 1/20 0.34
TP53 P04637 1/20 0.34
GLA P06280 1/20 0.34
CYP3A4 P08684 1/20 0.34
GAA P10253 1/20 0.34
ALOX12 P18054 1/20 0.34
NFKB1 P19838 1/20 0.34
CA12 O43570 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
RAB9A P51151 1/20 0.33
MMP13 P45452 1/20 0.33
HPGD P15428 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5511341 0.85 POLB (0.38) KMT2AMEN1POLBALDH1A1TSHR
SCHEMBL1867646 0.77 CA14 (0.32)
SCHEMBL1863476 0.73 MMP13 (0.38) F2KMT2AMEN1POLBALDH1A1
SCHEMBL17205742 0.69 ALDH1A1 (0.51) KMT2AMEN1ALDH1A1CYP3A4CA12
SCHEMBL3497445 0.69 POLB (0.51) F2KMT2AMEN1POLBALDH1A1
SCHEMBL1862267 0.68 MMP13 (0.39) KMT2AMEN1ALDH1A1TSHRKDM4E
SCHEMBL17205595 0.68 ALDH1A1 (0.53) KMT2AMEN1ALDH1A1CYP3A4GAA
SCHEMBL17206111 0.67 ALDH1A1 (0.51) KMT2AMEN1ALDH1A1TSHRCYP3A4
SCHEMBL1862912 0.66 MMP13 (0.37) F2KMT2AMEN1POLBALDH1A1
SCHEMBL9466282 0.66 KMT2A (0.45) KMT2AMEN1ALDH1A1CYP3A4GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455521-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-06-04 US disclosed
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. 2011-05-05 US disclosed
US-7754737-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-07-13 US disclosed
US-20090018103-A1 Diaminoalkane Aspartic Protease Inhibitors VITAE PHARMACEUTICAL, INC (US) 2009-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105506-A1 Diaminoalkane aspartic protease inhibitors DNPEP, PEPD, ACE F2 385/4885KMT2A 2621/4885MEN1 2596/4885
US-20090018103-A1 Diaminoalkane Aspartic Protease Inhibitors DNPEP, PEPD, ACE F2 385/4885KMT2A 2621/4885MEN1 2596/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.